- Call or text: +1 (808) 261-4476
- Mon-Fri (8:30am - 4:30pm) Lunch Break 12:30pm-1:30pm
- [email protected]
Edit Content
Conditions | Indications | Study Name | Treatment/MOA | NIH Website | Who Qualifies |
---|---|---|---|---|---|
Alzheimer’s Memory | MCI, Mild Mod AD | PRESENCE AD | PO LY3154207 (Mevidalen) D1 Receptors | NCT06538116 | MMSE 13-24 |
Alzheimer’s Memory | MCI, Mild AD | BRAINSHUTTLE | IV RO7126209 (Trontinemab) | NCT04639050 | MMSE 22-30 |
Alzheimer’s Memory | MCI, Mild AD | PO Buntanetap (Neuroprotective) | MMSE 21-28 | ||
Alzheimer’s Memory | MCI, Mild AD | IV VHB937 (TREM2 Activator) | CDR 0.5-1 | ||
Alzheimer’s Memory | AD, Agitation | PO NMRA-323511 V1a Receptor | NCT06546995 | MMSE 5-24 | |
Parkinson’s | Early PD | LUMA | PO BIIB1222 - LRRK2 - DMT | NCT05348785 | PD within 2 years |
Parkinson’s | PD with Motor Fluctuations | PO Lu AF28996 – D1 D2 Agonist | NCT04291859 | > 1.5 hr OFF | |
Epilepsy | Focal Seizure | RISE 2 | PO BHV-7000 VG Potassium channel | NCT06132893 | > 4 seizures/month |
Epilepsy | Focal Seizure | X-TOLE2 | PO XEN1101 Novel Potassium channel | NCT05614063 | > 4 seizures/month |
Epilepsy | Primary Generalized | X-TOLE3 | PO XEN1101 Novel Potassium channel | NCT05667142 | 3 PGTC in 8 weeks |
Epilepsy | Focal or Generalized | STARS | Inhaled Abortive EP0162 Staccato Alprazolam | NCT05077904 | Seizures |
MS Neuroimmunology | RRMS | IV ABP 692 vs Ocrevus | EDSS ≤ 5.5 ≥ 2 relapse ≤ 2 years |
||
Neuromuscular | CIDP | HYbISCUE | IV HyQvia | NCT06538064 | CIDP 2021 Guidelines |
Neuromuscular | Myasthenia Gravis | APPRAISE | PO LNP023 (Iptacopan) | NCT06517758 | MGFA Class II-IV |
Neuromuscular | Spasticity | DIRECTION | IM Dysport Abobotulinumtoxin A | NCT04936542 | Spasticity > 3 mths |
Pain | Migraine | PIONEER | PO LAHV/LAHW/Lasmiditan | NCT04396236 | Migraine > 6 mths |
Pain | Migraine Menstrual | MOSAIC | PO Ubrogepant | Migraine > 12 months 2 out of 3 are menstrual |
|
Psychiatric Neuro | Post Partum Dépression | RECONNECT | SQ RE 104 | NCT06342310 | DSM5 Post PD |
Psychiatric Neuro | Adjustment Disorder in ALS, MS, Parkinson’s | ADCO | SQ RE 104 | AjD > 4 weeks | |
Rare Neuro Diseases | Dentatorubral-Pallidoluysian Atrophy | Intrathecal nL-ATN-002 ASO Therapy | FDA IND 173123-Open label single center single patient |
Principal Investigator, Clinical Research Center Hawaii Pacific Neuroscience Clinical Professor, Dept. of Medicine (Neurology), Graduate Faculty, Clinical & Translational Research University of Hawai`i John Burns School of Medicine
Neurology
Neuroscience Chair
Director, Memory Disorders Center, Comprehensive Epilepsy Center, Neuro COVID Clinic, Center for Neuromodulation, Hawaii Pacific Neuroscience
Principal Investigator, Clinical Research Center, BRITL (Brain Research, Innovation & Translation Labs) BCI (Brain Computer Interface) & Brain Mapping Lab
Clinical Professor of Medicine (Neurology), Graduate Faculty, Clinical & Translational Research, University of Hawai`i John A. Burns School of Medicine